The program's focus has been to increase the receptor residency time to make OMass' antagonists resistant to competition by the endogenous ligand, which may allow all patients suffering from conditions related to ACTH excess, including congenital adrenal hyperplasia and Cushing's syndrome, to be treated.
To support the progress, OMass has added to its US and UK development team. Based in the USA, Dr Steve Griffen joined as vice president of clinical development, and Angela Hecyk joined as director of clinical operations. Based in the UK, Stuart Hadley has been appointed Senior Director of Chemistry Manufacture and Controls (CMC).
Ros Deegan, Chief Executive Officer at OMass Therapeutics, commented:
Nomination of our first clinical candidate represents a key milestone for the company. I am delighted to welcome Steve, Angela and Stuart to the OMass team. They bring extensive experience, and I have no doubt that they will prove to be invaluable additions as we progress our MC2 program to the clinic.
Steve Griffen, Vice President of Clinical Development at OMass Therapeutics, added:
I’m very excited by the opportunity to join OMass at such a pivotal time for the company. I look forward to working closely with Ros, Stuart, Angela and the rest of the OMass team in advancing our pipeline of small molecule drug candidates.
For more information, visit https://www.omass.com/